OncoSec Medical Announces October Events Agenda
September 30 2014 - 6:02AM
Business Wire
Company Also Provides Update on Data Presented
at ESMO 2014 Congress
OncoSec Medical Inc. (OTCQB: ONCS), a company developing
DNA-based intratumoral cancer immunotherapies, will attend or
present at three events in October. The company’s agenda includes a
number of high-profile scientific and investment conferences,
following a recent presentation of data at the ESMO 2014
Congress.
Robert H. Pierce, M.D., Chief Scientific Officer said, “It was a
great opportunity to be able to present our latest correlative data
on IL-12 electroporation at ESMO. In this presentation, we were
able to show how our transcriptional analysis of treated melanoma
patient samples mirrors what we have seen in the B16 syngeneic
mouse tumor model. This gives us increased confidence that our
model truly reflects what is happening in patients. These data,
which demonstrate that intratumoral IL-12 electroporation is
generating a systemic anti-tumor immune response, provide strong
support for moving forward with a combination of intratumoral IL-12
electroporation and an anti-PD-1 therapeutic.”
For more information on data presented at the ESMO 2014
Congress, please contact OncoSec Medical directly via the
information below.
Cancer Vaccines and Gene Therapy MeetingTu Diep, Vice
President of Operations, will present a discussion titled “Clinical
Response and Immune Correlates of Intratumoral Electroporation of
IL-12 in Advanced Melanoma” at the 2nd Annual Cancer Vaccines and
Gene Therapy (CVGT) Meeting. The meeting will take place October
6-7, 2014 at The Desmond in Malvern, Pennsylvania. Mr. Diep’s
presentation will begin at 11 AM EST on Tuesday, October 7.
The 2nd Annual CVGT Meeting will bring together important field
leaders to present and discuss the latest approaches and
technologies used to develop promising anti-cancer therapeutics.
The agenda will feature presentations and interactive discussions
designed to maximize the potential of cancer immunotherapeutics and
implement strategies to ensure successful cancer vaccine
development. For more information, please visit
http://www.ngtcancervaccines.com/index.html
BIO Investor ForumPunit Dhillon, President and CEO, will
present a corporate overview of the company at the 13th Annual BIO
Investor Forum, taking place October 7-8, 2014 at The Palace Hotel
in San Francisco, California. Mai H. Le, M.D., OncoSec’s newly
appointed Chief Medical Officer, will also be attending this
industry-leading event. The presentation is scheduled to begin at 9
AM PST on Tuesday, October 7 in the Presidio Room.
One hour after the presentation, a webcast will be made
available via the following link:
http://www.veracast.com/webcasts/bio/investorforum2014/11102154601.cfm
An archived version of the webcast will be available in the
“Events” section of the OncoSec web page at
http://www.oncosec.com
The BIO Investor Forum is an international biotech investor
conference focused on early and established private companies as
well as emerging public companies like OncoSec Medical. The event
features plenary sessions, business roundtables and therapeutic
workshops, company presentations, and one-on-one partnering
meetings, as part of an agenda designed to facilitate meaningful
discussion among investors and industry leaders. For more
information, please visit
http://www.bio.org/events/conferences/13th-annual-bio-investor-forum
Biotech CEO MeetingMr. Dhillon will participate in the
27th Annual Biotech CEO Meeting, taking place October 12-14,
2014 at The Montage in Laguna Beach, California.
The 27th Annual Biotech CEO Meeting will bring together a select
group of biotech and pharma CEOs to take part in a unique and
interactive networking event. The meeting is designed to provide a
comprehensive platform for open discussion, debate and problem
solving among CEO peers.
About OncoSec Medical Inc.OncoSec Medical Inc. is a
biopharmaceutical company developing its ImmunoPulse immunotherapy
to treat solid tumors. OncoSec Medical's core technology is
designed to enhance the local delivery and uptake of DNA
IL-12 and other DNA-based immune-modulating agents. Clinical
studies of ImmunoPulse have demonstrated an acceptable safety
profile and preliminary evidence of anti-tumor activity in the
treatment of various skin cancers, as well as the potential to
initiate a systemic immune response without the systemic toxicities
associated with other treatments. OncoSec's clinical programs
currently include three Phase 2 trials targeting metastatic
melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma,
conducted in collaboration with several prominent academic medical
centers. As the company continues to evaluate ImmunoPulse in these
indications, it is also investigating additional indications and
combination therapeutic approaches. For more information, please
visit www.oncosec.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management’s current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical’s filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
Investor Relations:OncoSec Medical Inc.Jordyn Kopin,
855-662-6732investors@oncosec.comorPublic Relations:Dian
Griesel, Int’l.Laura Radocaj, 212-825-3210lradocaj@dgicomm.com
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Aug 2024 to Sep 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Sep 2023 to Sep 2024